Table 3.

Prespecified events of clinical importance—incidence proportion (95% CI)

Event, n, % (95% CI)	ApoE ε4 carrier study		ApoE ε4 noncarrier study
	Placebo	BAP 0.5	Placebo	BAP 0.5	BAP 1.0
	(n = 439)	(n = 654)	(n = 344)	(n = 267)	(n = 263)
ARIA-E	9	109	2	13	31
	2.05	16.67	0.58	4.87	11.79
	(0.94, 3.86)	(13.89, 19.75)	(0.07, 2.08)	(2.62, 8.18)	(8.15, 16.3)
Intracranial hemorrhage	5	6	7	2	1
	1.14	0.92	2.03	0.75	0.38
	(0.37, 2.64)	(0.34, 1.99)	(0.82, 4.15)	(0.09, 2.68)	(0.01, 2.10)
Seizures/convulsions	1	7	3	1	0
	0.23	1.07	0.87	0.37	0.00
	(0.01, 1.26)	(0.43, 2.19)	(0.18, 2.53)	(0.01, 2.07)	(0.00, 1.39)
DVT/PE	2	8	0	1	1
	0.46	1.22	0.00	0.37	0.38
	(0.06, 1.64)	(0.53, 2.40)	(0.00, 1.07)	(0.01, 2.07)	(0.01, 2.10)
Hypersensitivity reactions	19	18	6	5	4
	4.33	2.75	1.74	1.87	1.52
	(2.63, 6.68)	(1.64, 4.32)	(0.64, 3.76)	(0.61, 4.32)	(0.42, 3.85)
Intraparenchymal hemorrhage	2	5	0	0	0
	0.46	0.76	0.00	0.00	0.00
	(0.06, 1.64)	(0.25, 1.78)	(0.00, 1.07)	(0.00, 1.37)	(0.00, 1.39)

ApoE apolipoprotein E, ARIA-E amyloid-related imaging abnormalities, edema/effusion, BAP bapineuzumab, DVT/PE deep vein thrombosis/pulmonary embolism